Aligos Therapeutics Inc
NASDAQ:ALGS

Watchlist Manager
Aligos Therapeutics Inc Logo
Aligos Therapeutics Inc
NASDAQ:ALGS
Watchlist
Price: 20.04 USD 1.26% Market Closed
Market Cap: 71.9m USD
Have any thoughts about
Aligos Therapeutics Inc?
Write Note

Relative Value

The Relative Value of one ALGS stock under the Base Case scenario is 13.75 USD. Compared to the current market price of 20.04 USD, Aligos Therapeutics Inc is Overvalued by 31%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ALGS Relative Value
Base Case
13.75 USD
Overvaluation 31%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
64
vs Industry
74
Median 3Y
73.5
Median 5Y
73.5
Industry
7.7
Forward
20.4
vs History
vs Industry
Median 3Y
-10.5
Median 5Y
-11.5
Industry
22.7
Forward
-2.8
vs History
vs Industry
Median 3Y
-12.1
Median 5Y
-12.9
Industry
21.6
vs History
vs Industry
Median 3Y
-11.9
Median 5Y
-12.7
Industry
25.2
vs History
82
vs Industry
67
Median 3Y
9.9
Median 5Y
13.9
Industry
2.5
vs History
vs Industry
85
Median 3Y
64.5
Median 5Y
64.5
Industry
7.7
Forward
-1.7
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9
vs History
19
vs Industry
16
Median 3Y
-9.5
Median 5Y
-9.7
Industry
4.2
Forward
0.1
vs History
15
vs Industry
15
Median 3Y
-9.3
Median 5Y
-10.9
Industry
4.1
Forward
0.1
vs History
15
vs Industry
19
Median 3Y
-10.6
Median 5Y
-11.3
Industry
5.7
vs History
15
vs Industry
15
Median 3Y
-10.5
Median 5Y
-11.2
Industry
3.6
vs History
vs Industry
74
Median 3Y
56.5
Median 5Y
59.3
Industry
4.6

Multiples Across Competitors

ALGS Competitors Multiples
Aligos Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Aligos Therapeutics Inc
NASDAQ:ALGS
69.1m USD 11.5 -0.9 0.1 0.1
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 083 264.3 -181 004.1 -219 796.6 -217 288.5
US
Abbvie Inc
NYSE:ABBV
312.7B USD 5.6 61.5 15.3 23.6
US
Amgen Inc
NASDAQ:AMGN
158.3B USD 4.9 37.4 17.5 33.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD 10.9 -241.6 24 25.2
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD 4 891.9 9.9 9.9
US
Epizyme Inc
F:EPE
94.1B EUR 1 849.9 -472 -514.1 -500.3
AU
CSL Ltd
ASX:CSL
133.6B AUD 5.9 32.9 20.3 25.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD 5.9 17.8 16.2 18
US
Seagen Inc
F:SGT
39.3B EUR 17.8 -54.6 -58.7 -53
NL
argenx SE
XBRU:ARGX
34.5B EUR 18.5 -129.9 -104.5 -76.2
P/E Multiple
Earnings Growth
US
Aligos Therapeutics Inc
NASDAQ:ALGS
Average P/E: 208.3
Negative Multiple: -0.9
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -181 004.1 N/A
US
Abbvie Inc
NYSE:ABBV
61.5
412%
US
Amgen Inc
NASDAQ:AMGN
37.4
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -241.6
42%
US
Gilead Sciences Inc
NASDAQ:GILD
891.9
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472 N/A
AU
CSL Ltd
ASX:CSL
32.9
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.6 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -129.9 N/A
EV/EBITDA Multiple
EBITDA Growth
US
Aligos Therapeutics Inc
NASDAQ:ALGS
Average EV/EBITDA: 14.7
0.1
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 796.6 N/A
US
Abbvie Inc
NYSE:ABBV
15.3
29%
US
Amgen Inc
NASDAQ:AMGN
17.5
62%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
43%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
16%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.1 N/A
AU
CSL Ltd
ASX:CSL
20.3
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
35%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -104.5 N/A
EV/EBIT Multiple
EBIT Growth
US
Aligos Therapeutics Inc
NASDAQ:ALGS
Average EV/EBIT: 19.3
0.1
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 288.5 N/A
US
Abbvie Inc
NYSE:ABBV
23.6
88%
US
Amgen Inc
NASDAQ:AMGN
33.1
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.2
44%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -500.3 N/A
AU
CSL Ltd
ASX:CSL
25.3
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.2 N/A

See Also

Discover More
Back to Top